Dr. Lustig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
TRC 2 West
3400 Civic Center Blvd
Philadelphia, PA 19104Phone+1 215-662-2428Fax+1 215-349-5445
Summary
- Dr. Robert Lustig, based in Philadelphia, PA, is a specialist in Radiation Oncology with subspecialties in Central Nervous System Cancer and Pediatric Radiation Oncology. He completed his medical education at Sidney Kimmel Medical College at Thomas Jefferson University, with residency training in Radiation Oncology also at Thomas Jefferson University. Since 1998, he has been an attending physician at the Hospital of the University of Pennsylvania. Dr. Lustig has expertise in treating skin cancer, gliomas, and glioblastoma multiforme. His research contributions include several published studies on glioblastoma, proton therapy, and pediatric cancer, with notable publications in Neuro-Oncology and Scientific Reports. He has been involved in clinical trials focused on innovative imaging and radiation therapy techniques. Dr. Lustig received the CMS Meaningful Use Stage 1 Certification from Epic Systems in 2012-2013. In 2023 he retired from full time practice.
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Radiation Oncology, 1973 - 1976
- New York Medical College (Metropolitan)Residency, Internal Medicine, 1970 - 1971
- Hoboken University Medical CenterInternship, Internal Medicine, 1969 - 1970
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1969
Certifications & Licensure
- PA State Medical License 1973 - 2026
- NJ State Medical License 1976 - 2025
- NC State Medical License 2020 - 2022
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Start of enrollment: 2005 Oct 01
- Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Start of enrollment: 2009 Dec 17
- Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study Start of enrollment: 2010 Sep 01
Publications & Presentations
PubMed
- Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma.Fabio M Iwamoto, Shyam K Tanguturi, Lakshmi Nayak, Tony J Wang, Arati Desai
Clinical Cancer Research. 2025-01-17 - Machine Learning-based Prognostic Subgrouping of Glioblastoma: A Multi-center Study.Hamed Akbari, Spyridon Bakas, Chiharu Sako, Anahita Fathi Kazerooni, Javier Villanueva-Meyer
Neuro-Oncology. 2024-12-12 - 2 citationsA Prospective Phase I/II Clinical Trial of High-Dose Proton Therapy for Chordomas and Chondrosarcomas.Sana S Dastgheyb, Alexandra D Dreyfuss, Michael J LaRiviere, Jahan J Mohiuddin, Brian C Baumann
Advances in Radiation Oncology. 2024-05-01
Press Mentions
- Patient Empowerment Platform "Health Storylines" from Self Care Catalysts Is Being Studied at Penn's Roberts Proton Therapy CenterSeptember 21st, 2016
Professional Memberships
- Society of Neuro-OncologyMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: